Sign inJoin
Company / Finance

AC Immune SA

ACIU · NASDAQ

AC Immune has partner-backed Alzheimer's programs, a Parkinson's active immunotherapy readout, a new NLRP3 Phase 1 asset, and CHF 74.8 million of Q1 2026 cash resources. The hard question is whether 2026 milestones can turn platform promise into partner commitment before the runway becomes the thesis.

FollowAdd to WatchlistAsk Question
NASDAQACIUCoverage BootstrapBiotechnologyNeurodegenerationAlzheimer's Disease
Latest ReportMay 13, 2026AC Immune: five neurodegeneration shots before the 2027 cash clock ringsView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 company reports
Latest Thesis

AC Immune: five neurodegeneration shots before the 2027 cash clock rings

AC Immune has partner-backed Alzheimer's programs, a Parkinson's active immunotherapy readout, a new NLRP3 Phase 1 asset, and CHF 74.8 million of Q1 2026 cash resources. The hard question is whether 2026 milestones can turn platform promise into partner commitment before the runway becomes the thesis.

May 13, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
AC Immune SAImmune: five neurodegeneration shots before the 2027 cash clock May 13, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
AC Immune: five neurodegeneration shots before the 2027 cash clock ringsAC Immune has partner-backed Alzheimer's programs, a Parkinson's active immunotherapy readout, a new NLRP3 Phase 1 asset, and CHF 74.8 million of Q1 2026 cash resources. The hard question is whether 2026 milestones can turn platform promise into partner commitment before the runway becomes the thesis.NASDAQMay 13, 2026Research reportReadSlides